Trials / Completed
CompletedNCT03737851
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | elezanumab | solution for infusion |
| DRUG | placebo | solution for infusion |
Timeline
- Start date
- 2018-12-11
- Primary completion
- 2021-08-09
- Completion
- 2021-09-09
- First posted
- 2018-11-13
- Last updated
- 2023-12-22
- Results posted
- 2023-12-22
Locations
49 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03737851. Inclusion in this directory is not an endorsement.